- RecruitingPHASE3
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
This study looks at new drug combinations for a specific type of advanced lung cancer. It compares a new drug, Divarasib, with Pembrolizumab, against standard treatments to see which works best and is safest for patients with KRAS G12C-mutated non-small cell lung cancer.
For: Non-Small Cell Lung Cancer · KRAS G12C Lung CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
This study offers continued treatment to cancer patients already in certain Genentech/Roche studies. It's for those still benefiting from their current treatment and who can't get it elsewhere. The aim is to bridge care for these patients.
For: CancerBelgium · Canada · China - RecruitingPHASE1
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
This study looks at new treatments for bowel cancer that has spread. We want to see if these targeted medicines or immunotherapy are safe and work well for people whose cancer has specific genetic features, which we call biomarkers.
For: Metastatic Colorectal CancerUnited States · Australia · Canada - RecruitingPHASE1, PHASE2
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
This study looks at a new drug, Divarasib, for advanced lung cancer with a specific gene change (KRAS G12C). It checks if the drug is safe, how it works, and if it can shrink tumours, either alone or with other cancer treatments.
For: Non-Small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE2, PHASE3
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
This study looks at new drug combinations for advanced non-small cell lung cancer. It aims to find out how safe and effective these treatments are for people whose cancer has specific genetic changes, using blood tests to identify these changes.
For: Non-Small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
This study looks at a new drug, divarasib, for advanced lung cancer with a specific genetic change (KRAS G12C). It compares divarasib to existing treatments, sotorasib or adagrasib, to see how well they work and if they are safe.
For: Non-Small Cell Lung Cancer · KRAS G12C Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE2
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
This study is for people with advanced solid cancers that haven't responded to other treatments. It uses a "precision medicine" approach, matching treatments to the specific genetic changes found in each person's tumour, aiming for more effective and personalised care.
For: Solid TumorsUnited States · Australia · Belgium